資源描述：
《健肝顆粒聯(lián)合經(jīng)導(dǎo)管動(dòng)脈栓塞術(shù)治療原發(fā)性肝癌臨床療效研究-論文.pdf》由會(huì)員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在應(yīng)用文檔-天天文庫。
1、中西醫(yī)結(jié)合肝病雜志2013年第23卷第5期·259··臨床論著·doi：10．3969／j．issn．1005-0264．2013．05．002健肝顆粒聯(lián)合經(jīng)導(dǎo)管動(dòng)脈栓塞術(shù)治療原發(fā)性肝癌臨床療效研究黃古葉羅耀昌龍富立李慧貞胡振斌黃軍禎。黃德佳呂建林1．廣西中醫(yī)藥大學(xué)第一附屬醫(yī)院肝病科廣西中醫(yī)肝病治療中心(廣西南寧，530023)2．廣西中醫(yī)藥大學(xué)第一附屬醫(yī)院放射介人中心摘要目的：觀察健肝顆粒聯(lián)合經(jīng)導(dǎo)管動(dòng)脈栓塞術(shù)(transcatheterarterialchemoembolization，TACE)治療HBVDNA陽性原發(fā)性肝癌
2、(HCC)的效果及其預(yù)后。方法：HBVDNA>10Iu／ml的HCC患者126例，均予核苷類似物藥抗病毒治療，并隨機(jī)分為TACE聯(lián)合健肝顆粒的治療組(62例)和TACE治療的對照組(64例)，觀察兩組患者肝功能Child—Pugh評(píng)分、HBVDNA定量、實(shí)體瘤體積變化和兩年生存率。結(jié)果：治療兩年后，治療組患者肝功能Child—Pugh評(píng)分較對照組降低，且治療組患者兩年生存率比對照組高，其差異均有統(tǒng)計(jì)學(xué)意義(P<0．05)；實(shí)體瘤縮小和HBVDNA定量變化兩組比較差異無統(tǒng)計(jì)學(xué)意義(P>0．05)。結(jié)論：健肝顆粒聯(lián)合TACE治療可改
3、善HCC患者的肝功能，提高其生存率和生活質(zhì)量。關(guān)鍵詞原發(fā)性肝癌；健肝顆粒／治療應(yīng)用；經(jīng)導(dǎo)管動(dòng)脈栓塞術(shù)；臨床療效EficacyofJiangangranulescombinedwithtranscatheterarterialchemoem-bolizati0nf10rtreatmentofhepatocellularcarcinomaHUANGGU-YE，LUOYAO-CHANG，LONGFU-LI，eta1．1．DepartmentofHepatology，TheFirstHospital，GuangxiTra—ditiona
4、lChineseMedicalUniversity(NanningGuangxi，530023)ChinaAbstract0bjecfive：ToinvestigatetheeficacyoftheadditionoftheJian-gangranulestotranscatheterarterialchemoem-bolization(TACE)inpatientswithhepatitisBvirusHBVDNA—positivehepatocellularcarcinoma(HCC)whoreceivedantiviral
5、therapywithnucleosideanalogues．Methods：Onehundredandtwenty-sixHCCpatientswithHBVDNA>10IU／mlwerein—cluded．Allpatientsreceivedantiviraltherapywithnucleosideanalogues．ThentheywererandomlyassignedtoreceiveTACEa—lone(n=64)orincombinationwiththeJian—gangranules(n=62)．Two—y
6、earsurvivalandchangesinChild-Pughscores，HBVDNAlevelsandsolidtumorvolumewereassessed．Results：At1and2years，patientsreceivingtheadditionalJian—gangranuleshadsignificantlylowerChild—Pughscoresandhigher2-yea／"survivalcomparedwithcontrols(P<0．05)．Therewerenostatisticallysi
7、gnificantdifferencesinchangesinsolidtumorvolumeorHBVDNAlevelsbetweenthetwogroups(P>0．05)．Conclusion：TheJian-gangranulescombinedwithTACEmayimproveliverfunction，survivalandqualityoflifeinpatientswithHCC．KeyWordshepatocellularcarcinoma；Jian—gangranules／therapeuticapplic
8、ation，transcatheterarterialchemoemboliza-tion；clinicaleficacy．中晚期肝癌外科手術(shù)切除率低、預(yù)后差，臨床多遠(yuǎn)期療效仍不理想。WHO肝癌預(yù)防會(huì)議指出，HBV以經(jīng)導(dǎo)管動(dòng)脈栓塞術(shù)(TACE)和支持治療為主，但
